sch 34826 has been researched along with Hypoxia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnal, F; Hill, NS; Klinger, JR; Petit, RD; Warburton, RR; Wrenn, DS | 1 |
| Morice, AH; Sheedy, W; Stewart, AG; Thompson, JS | 1 |
2 other study(ies) available for sch 34826 and Hypoxia
| Article | Year |
|---|---|
Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats.
Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Chronic Disease; Cyclic GMP; Dioxolanes; Dipeptides; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Imidazoles; Male; Muscle, Smooth, Vascular; Myocardium; Neprilysin; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1993 |
Effects of SCH 34826, a neutral endopeptidase inhibitor, on hypoxic pulmonary vascular remodelling.
Topics: Analgesics; Animals; Atrial Natriuretic Factor; Dioxolanes; Dipeptides; Hypoxia; Injections, Subcutaneous; Male; Neprilysin; Pulmonary Artery; Rats; Rats, Inbred Strains | 1992 |